Page last updated: 2024-10-21

2-amino-5-phosphonovalerate and Diabetic Neuropathies

2-amino-5-phosphonovalerate has been researched along with Diabetic Neuropathies in 1 studies

2-Amino-5-phosphonovalerate: The D-enantiomer is a potent and specific antagonist of NMDA glutamate receptors (RECEPTORS, N-METHYL-D-ASPARTATE). The L form is inactive at NMDA receptors but may affect the AP4 (2-amino-4-phosphonobutyrate; APB) excitatory amino acid receptors.

Diabetic Neuropathies: Peripheral, autonomic, and cranial nerve disorders that are associated with DIABETES MELLITUS. These conditions usually result from diabetic microvascular injury involving small blood vessels that supply nerves (VASA NERVORUM). Relatively common conditions which may be associated with diabetic neuropathy include third nerve palsy (see OCULOMOTOR NERVE DISEASES); MONONEUROPATHY; mononeuropathy multiplex; diabetic amyotrophy; a painful POLYNEUROPATHY; autonomic neuropathy; and thoracoabdominal neuropathy. (From Adams et al., Principles of Neurology, 6th ed, p1325)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Calcutt, NA1
Chaplan, SR1

Other Studies

1 other study available for 2-amino-5-phosphonovalerate and Diabetic Neuropathies

ArticleYear
Spinal pharmacology of tactile allodynia in diabetic rats.
    British journal of pharmacology, 1997, Volume: 122, Issue:7

    Topics: 2-Amino-5-phosphonovalerate; Analgesics, Non-Narcotic; Analgesics, Opioid; Animals; Anti-Bacterial A

1997